Publications by authors named "Gregory Fontenot"
Objectives: To determine the relative concentrations of enclomiphene (ENC) and zuclomiphene (ZUC) isomers in men with hypogonadism on long-term clomiphene citrate (CC) therapy, and to determine whether patient age, body mass index (BMI) or duration of therapy were predictive of relative concentrations of ENC and ZUC.
Patients And Methods: Men already receiving CC 25 mg daily therapy for secondary hypogonadism for a minimum of 6 weeks were recruited to have their ENC and ZUC levels assessed. Total testosterone, free testosterone, oestradiol, follicle stimulating hormone (FSH), and luteinizing hormone (LH) before initiation of and while on CC therapy were recorded for all patients.
The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S.
View Article and Find Full Text PDFObjectives: To determine, in a chronic dosing study, the oral toxicity potential of the test substances, enclomiphene citrate (ENC) and zuclomiphene citrate (ZUC), when administered to male mice by oral gavage.
Materials And Methods: Mice were divided into five treatment groups. Group I, placebo; Group II, 40 mg/kg body weight/day ENC; Group III, 4 mg/kg/day ENC; Group IV, 40 mg/kg/day ZUC; Group V, 4 mg/kg/day ZUC.
Objective: To determine the effect of enclomiphene citrate in men with secondary hypogonadism.
Design: Phase II clinical trial.
Setting: Community dwelling men making visits to physician offices.
Objectives: To determine the pharmacodynamic (PD) profile of serum total testosterone levels (TT) and luteinizing hormone (LH) in men with secondary hypogonadism following initial and chronic daily oral doses of enclomiphene citrate in comparison to transdermal testosterone. To determine the effects of daily oral doses of enclomiphene citrate (Androxal®) in comparison to transdermal testosterone on other hormones and markers in men with secondary hypogonadism.
Patients And Methods: This was a randomized, single blind, two-center phase II study to evaluate three different doses of enclomiphene citrate (6.
Article Synopsis
- Researchers created a high-throughput method to knockout mouse versions of potential drug targets in the human genome to study body fat regulation.
- They used dual-energy X-ray absorptiometry (DXA) technology to measure body fat in knockout (KO) and wild-type (WT) mice, finding that their data showed a normal distribution.
- The study identified specific KO lines associated with lean and obese phenotypes, confirming their findings with additional cohorts, and demonstrating that the screening method can effectively identify important genes involved in body fat regulation.